Press release
Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments
Total revenues, which consist of net product revenues and collaboration revenues, for the first quarter 2023 totaled $253.5 million Net product revenues for
About this update from Sarepta Therapeutics, Inc.
[{"type":"text","content":"\n\nTotal revenues, which consist of net product revenues and collaboration revenues, for the first quarter 2023 totaled $253.5 million\n\n\n\nNet product revenues for the first quarter 2023 totaled $231.5 million, a 23% increase over the same quarter of prior year\n\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2023.\n\n\n“We are pleased to report another strong quarter of performance serving the Duchenne community. With EXONDYS 51, VYONDYS 53, and AMONDYS 45, we once again exceeded analyst estimates, with total revenue for the quarter reaching $253.5 million and net product revenue standing at $231.5 million and growing at 23% versus the same quarter of prior year. The Sarepta team has consistently performed and served the patient community over the last 6 years and it will be this team, with its track record of success, that will launch and serve the community in the United States with SRP-9001 if our BLA is approved,” said Doug Ingram, president and chief executive officer, Sarepta. “We look forward to sharing the totality of evidence supporting the safety and efficacy of SRP-9001 at the upcoming advisory committee meeting on May 12 and at the same time continuing to prepare for the launch of SRP-9001 in the United States.”\n\n\nFirst Quarter 2023 and Recent Developments:\n\n\n\nFDA advisory committee meeting for SRP-9001 to be held on May 12, 2023: In March, the Company announced that at its late cycle meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA), the U.S. Food and Drug Administration’s Office of Therapeutic Products determined that an advisory committee meeting will be held for SRP-9001 in advance of the May 29, 2023 regulatory action date. In April, Sarepta announced May 12, 2023 as the date of the U.S. Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee meeting for the SRP-9001 BLA. The advisory committee meeting will be hosted as a virtual meeting. SRP-9001 is Sarepta’s investigational gene therapy for the treatment of Duchenne muscular dystrophy.\n\n\n\nSRP-5051-201 MOMENTUM Part B clinical trial fully enrolled: Sarepta has completed enrollment for Part B of the MOMENTUM clinical trial in...